-
1 week ago | 
hcplive.com | Chelsie Derman
A recent study highlights how artificial intelligence (AI) improves the prediction, diagnosis, treatment, and management of allergic diseases, including asthma, atopic dermatitis, food allergy, allergic rhinitis, and urticaria.1AI can analyze large volumes of textual, visual, and auditory data through techniques like Reinforcement Learning, Machine Learning, Deep Learning, and Natural Language Processing.
-
1 week ago | 
hcplive.com | Chelsie Derman
New research observed distinct convergent brain abnormalities in long-term sleep disorders and short-term sleep deprivation.1“We observed unique brain alterations across sleep disorders (bilateral sgACC and right amygdala and hippocampus) and sleep deprivation (right thalamus),” wrote investigators, led by Gerion M. Reimann, MSc, from the department of neurology at RWTH Aachen University, in Germany.
-
1 week ago | 
hcplive.com | Chelsie Derman
Last week, a multi-disciplinary group of healthcare providers and childcare professionals met to discuss how to best provide early childcare centers with resources to recognize and respond to severe allergic reactions in young children.1The Early Childhood Anaphylaxis Collaborative, spearheaded by Kaléo, strives to educate people on gaps in recognizing anaphylaxis in children < 5 years and provide guidance on stocking epinephrine that is not prescribed to a specific child.
-
2 weeks ago | 
hcplive.com | Chelsie Derman
Recent developments in psychiatry highlight both setbacks and emerging opportunities in treatment. Cobenfy (xanomeline-trospium) fell short in a phase 3 trial as an adjunctive schizophrenia therapy, though safety and subgroup findings point to future potential. Survey data revealed a disconnect between patient and provider preferences for long-acting antipsychotics, and another stressed the need for improved adherence strategies.
-
2 weeks ago | 
hcplive.com | Chelsie Derman
Although April brought no regulatory changes in allergy medication, various journals published studies on allergy treatments or associations in the allergy field. From new evidence supporting the effectiveness of omalizumab in IgE-mediated food allergy to a pediatric protocol improving anesthetic allergy diagnosis, the data reflect an evolving landscape.
-
2 weeks ago | 
hcplive.com | Chelsie Derman
A new study discovered that opioid use disorder (OUD) reduces the ability to savor natural, healthy pleasure, but this can be mitigated by cognitive interventions that include training in mindfulness and savoring.1In 2023, 8.9 million US individuals misused opioids, with 5.7 million having OUD. High opioid doses can have neuropsychopharmacologic effects on brain systems integral to reward processing, motivation, and emotion regulation, putting people at risk of OUD.
-
2 weeks ago | 
hcplive.com | Chelsie Derman
The US Food and Drug Administration (FDA) approved nipocalimab-aahu (IMAAVY™) to treat generalized myasthenia gravis (gMG) in adults and children (> 12 years) who are anti-acetylcholine receptor (AChR) or anti-muscular-specific kinase (MuSK) antibody positive.1,2 Announced by Johnson & Johnson on April 30, 2025, the approval of this human FcRn blocking monoclonal antibody marks the second agent on the market for both common subtypes of gMG, following the 2023 approval of rozanolixizumab...
-
2 weeks ago | 
consultantlive.com | Chelsie Derman
On April 28, 2025, Alto Neuroscience presented new data at the Society of Biological Psychiatry (SOBP) 2025 in Toronto showing that an EEG biomarker may help identify placebo responders in major depressive disorder (MDD) trials, a breakthrough that could improve the detection of a drug’s true therapeutic effect. Clinical trials on MDD have high placebo rates, often ranging between 35% to 45%. A 2019 analysis of 122 MDD trials found that active and placebo responses are highly correlated.
-
2 weeks ago | 
hcplive.com | Chelsie Derman
On April 28, 2025, Alto Neuroscience presented new data at the Society of Biological Psychiatry (SOBP) 2025 in Toronto showing that an EEG biomarker may help identify placebo responders in major depressive disorder (MDD) trials, a breakthrough that could improve the detection of a drug’s true therapeutic effect. Clinical trials on MDD have high placebo rates, often ranging between 35% to 45%. A 2019 analysis of 122 MDD trials found that active and placebo responses are highly correlated.
-
2 weeks ago | 
hcplive.com | Chelsie Derman
In a recent study, patients with hereditary α-tryptasemia (HαT) had a 13% prevalence of drug-induced anaphylaxis.1“This is the first report investigating HαT and α-tryptase genotypes as a risk factor for potentially life-threatening reactions in patients with drug allergy or hypersensitivity to biological agents,” wrote investigators, led by Peter Korošec, MD, from the University Clinic of Respiratory and Allergic Diseases in Slovenia.
